Moderna announced Tuesday that its coronavirus vaccine was 90% effective six months after a person received their second dose.
“Vaccine efficacy from two weeks after the second dose and based on updated resolved cases remains consistent with previous updates, including more than 90% against all cases of COVID-19 and more than 95% against severe cases of COVID-19 “. announced the company.
Modern is working to get its vaccine fully approved by the United States, as it is only under emergency authorizations from the Food and Drug Administration.
“The Moderna team continues to make significant progress with our COVID-19 vaccine,” said Stéphane Bancel, CEO of Moderna. “New preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants”
The study includes data from 900 cases of coronavirus, with more than 100 serious cases.
Along with the updated effectiveness of the vaccine, Moderna is currently working on its second phase to test in adolescents.
There are about 3,000 minors aged 12 to 17 fully enrolled in the Moderna trial and the company is working on enrolling children aged 6 months to 11 years.
The company aims to fully enroll 6,750 healthy pediatric participants in the U.S. and Canada.
The news of Moderna’s success comes when the FDA recommended that the administration of the Johnson & Johnson vaccine be paused due to concerns about blood clots.